Blood test may tame the tightrope walk of transplant drugs

This study tests whether a blood test called TruGraf can help doctors fine-tune immunosuppression medications in liver transplant recipients with autoimmune liver diseases like autoimmune hepatitis, primary sclerosing cholangitis, or primary biliary cirrhosis. The test measures gene expression to indicate whether the immune system is quiet or active, potentially allowing doctors to reduce drug doses safely without triggering rejection. Participants will have monthly blood draws for the first six months after transplant, and researchers will track graft survival, rejection episodes, and kidney function.